PODESTA GROUP, INC. for BRISTOL-MYERS SQUIBB
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. FDA issues. Diabetes drugs issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANNE MARIE POLAK | — |
| THOMAS B SPARKMAN | — |
Health Issues HCR
Diabetes issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Medical/Disease Research/Clinical Labs MED
Diabetes research issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Medicare/Medicaid MMM
Medicare coverage and reimbursement issues. Diabetes issues. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.